Symbols / QURE $15.77 -1.10%
QURE Chart
About
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 985.78M |
| Enterprise Value | 910.77M | Income | -198.97M | Sales | 16.10M |
| Book/sh | 3.19 | Cash/sh | 9.96 | Dividend Yield | — |
| Payout | 0.00% | Employees | 221 | IPO | — |
| P/E | — | Forward P/E | -6.05 | PEG | — |
| P/S | 61.24 | P/B | 4.94 | P/C | — |
| EV/EBITDA | -5.54 | EV/Sales | 56.58 | Quick Ratio | 9.99 |
| Current Ratio | 10.43 | Debt/Eq | 269.78 | LT Debt/Eq | — |
| EPS (ttm) | -3.46 | EPS next Y | -2.60 | EPS Growth | — |
| Revenue Growth | 6.60% | Earnings | 2026-05-07 | ROA | -16.21% |
| ROE | -207.10% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -9.01% | Profit Margin | 0.00% | Shs Outstand | 62.53M |
| Shs Float | 49.09M | Short Float | 20.41% | Short Ratio | 4.65 |
| Short Interest | — | 52W High | 71.50 | 52W Low | 7.76 |
| Beta | 0.77 | Avg Volume | 3.39M | Volume | 978.17K |
| Target Price | $38.26 | Recom | Buy | Prev Close | $15.94 |
| Price | $15.77 | Change | -1.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.23
Mean price target
2. Current target
$15.82
Latest analyst target
3. DCF / Fair value
$-30.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.82
Low
$8.89
High
$94.57
Mean
$38.23
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | up | Mizuho | Neutral → Outperform | $35 |
| 2026-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-03-09 | main | Chardan Capital | Buy → Buy | $31 |
| 2026-03-09 | up | RBC Capital | Sector Perform → Outperform | $35 |
| 2026-03-09 | up | Wells Fargo | Equal-Weight → Overweight | $60 |
| 2026-03-03 | main | Goldman Sachs | Neutral → Neutral | $9 |
| 2026-03-03 | down | Wells Fargo | Overweight → Equal-Weight | $15 |
| 2026-03-03 | main | Chardan Capital | Buy → Buy | $16 |
| 2026-03-03 | down | Mizuho | Outperform → Neutral | $12 |
| 2026-03-02 | up | Cantor Fitzgerald | Overweight → Neutral | $9 |
| 2026-02-24 | init | Wolfe Research | — → Peer Perform | — |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-01-28 | init | Barclays | — → Equal-Weight | $31 |
| 2025-12-11 | main | Stifel | Buy → Buy | $40 |
| 2025-12-09 | main | Mizuho | Outperform → Outperform | $33 |
| 2025-12-04 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-11-12 | main | Wells Fargo | Overweight → Overweight | $60 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-11-10 | main | Leerink Partners | Outperform → Outperform | $60 |
| 2025-11-04 | main | Goldman Sachs | Neutral → Neutral | $38 |
- FDA urges new trial for experimental Huntington's gene therapy AMT-130 - Stock Titan Mon, 02 Mar 2026 08
- QURE LAWSUIT ALERT: Levi & Korsinsky Notifies uniQure N.V. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire Wed, 11 Mar 2026 13
- QURE Stock Crashes 32% in a Week: Here's What You Should Know - Yahoo Finance Fri, 06 Mar 2026 08
- Uniqure Plummets By A Third After Realizing 'The Worst Case Scenario' For Its Gene Therapy - Investor's Business Daily Mon, 02 Mar 2026 08
- Why (QURE) Price Action Is Critical for Tactical Trading - Stock Traders Daily Fri, 13 Mar 2026 16
- uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE - GlobeNewswire hu, 12 Mar 2026 02
- uniQure N.V. (NASDAQ:QURE) Sees Significant Growth in Short Interest - MarketBeat Mon, 16 Mar 2026 18
- QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit - Stocktwits Wed, 11 Mar 2026 03
- Why uniQure (QURE) Is Up 59.1% After FDA Oversight Shift and AMT-130 Analyst Upgrades – And What's Next - simplywall.st Fri, 13 Mar 2026 08
- QURE Stock Crashes 32% in a Week: Here's What You Should Know - Zacks Investment Research Fri, 06 Mar 2026 08
- $QURE stock is up 32% today. Here's what we see in our data. - Quiver Quantitative Fri, 06 Mar 2026 19
- A Unique Situation For UniQure (QURE) - Seeking Alpha hu, 12 Mar 2026 18
- UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire hu, 12 Mar 2026 12
- Farallon Capital Management LLC Raises Position in uniQure N.V. $QURE - MarketBeat Mon, 16 Mar 2026 10
- QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits ue, 10 Mar 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 12000 | 108720 | — | Sale at price 9.06 per share. | KLEMT CHRISTIAN | Chief Financial Officer | — | 2026-03-04 00:00:00 | D |
| 1 | 3412 | 30913 | — | Sale at price 9.06 per share. | POTTS JEANNETTE | Officer | — | 2026-03-04 00:00:00 | D |
| 2 | 808 | 7320 | — | Sale at price 9.06 per share. | ABI-SAAB WALID | Officer | — | 2026-03-04 00:00:00 | D |
| 3 | 14581 | 132104 | — | Sale at price 9.06 per share. | KAPUSTA MATTHEW C | Chief Executive Officer | — | 2026-03-04 00:00:00 | D |
| 4 | 70600 | — | — | Stock Award(Grant) at price 0.00 per share. | KAPUSTA MATTHEW C | Chief Executive Officer | — | 2026-03-04 00:00:00 | D |
| 5 | 39600 | — | — | Stock Award(Grant) at price 0.00 per share. | KLEMT CHRISTIAN | Chief Financial Officer | — | 2026-03-04 00:00:00 | D |
| 6 | 35400 | — | — | Stock Award(Grant) at price 0.00 per share. | POTTS JEANNETTE | Officer | — | 2026-03-04 00:00:00 | D |
| 7 | 41700 | — | — | Stock Award(Grant) at price 0.00 per share. | ABI-SAAB WALID | Officer | — | 2026-03-04 00:00:00 | D |
| 8 | 19800 | — | — | Stock Award(Grant) at price 0.00 per share. | O'KEEFE KYLIE | Officer | — | 2026-03-04 00:00:00 | D |
| 9 | 12532 | 124693 | — | Sale at price 9.95 per share. | KLEMT CHRISTIAN | Chief Financial Officer | — | 2026-03-02 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 8.29M | -2.73M | -733.24K | 298.39K |
| TaxRateForCalcs | 0.26 | 0.26 | 0.26 | 0.01 |
| NormalizedEBITDA | -148.72M | -150.16M | -250.26M | -134.05M |
| TotalUnusualItems | 32.13M | -10.58M | -2.84M | 26.04M |
| TotalUnusualItemsExcludingGoodwill | 32.13M | -10.58M | -2.84M | 26.04M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -198.97M | -239.56M | -308.48M | -126.79M |
| ReconciledDepreciation | 14.76M | 12.64M | 11.90M | 8.54M |
| ReconciledCostOfRevenue | 1.69M | 7.80M | 3.78M | 3.34M |
| EBITDA | -116.59M | -160.75M | -253.10M | -108.02M |
| EBIT | -131.35M | -173.39M | -265.00M | -116.56M |
| NetInterestIncome | -45.03M | -42.33M | -22.00M | -11.10M |
| InterestExpense | 61.99M | 63.74M | 41.56M | 11.70M |
| InterestIncome | 16.97M | 21.41M | 19.56M | 609.00K |
| NormalizedIncome | -222.81M | -231.71M | -306.37M | -152.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -198.97M | -239.56M | -308.48M | -126.79M |
| TotalExpenses | 203.93M | 209.30M | 298.33M | 250.73M |
| RentExpenseSupplemental | 1.79M | 1.36M | 900.00K | 820.00K |
| TotalOperatingIncomeAsReported | -185.35M | -184.29M | -282.87M | -143.16M |
| DilutedAverageShares | 57.50M | 48.65M | 47.67M | 46.74M |
| BasicAverageShares | 57.50M | 48.65M | 47.67M | 46.74M |
| DilutedEPS | -3.46 | -4.92 | -6.47 | -2.71 |
| BasicEPS | -3.46 | -4.92 | -6.47 | -2.71 |
| DilutedNIAvailtoComStockholders | -198.97M | -239.56M | -308.48M | -126.79M |
| NetIncomeCommonStockholders | -198.97M | -239.56M | -308.48M | -126.79M |
| NetIncome | -198.97M | -239.56M | -308.48M | -126.79M |
| NetIncomeIncludingNoncontrollingInterests | -198.97M | -239.56M | -308.48M | -126.79M |
| NetIncomeContinuousOperations | -198.97M | -239.56M | -308.48M | -126.79M |
| TaxProvision | 5.63M | 2.43M | 1.92M | -1.47M |
| PretaxIncome | -193.34M | -237.13M | -306.56M | -128.26M |
| OtherIncomeExpense | 39.51M | -12.62M | -2.08M | 27.12M |
| OtherNonOperatingIncomeExpenses | 7.38M | -2.04M | 766.00K | 1.09M |
| SpecialIncomeCharges | 6.00M | -73.00K | -361.00K | 0.00 |
| GainOnSaleOfPPE | 6.00M | 0.00 | 0.00 | |
| GainOnSaleOfBusiness | 0.00 | 1.15M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 1.22M | 361.00K | 0.00 |
| GainOnSaleOfSecurity | 26.13M | -10.51M | -2.48M | 26.04M |
| NetNonOperatingInterestIncomeExpense | -45.03M | -42.33M | -22.00M | -11.10M |
| InterestExpenseNonOperating | 61.99M | 63.74M | 41.56M | 11.70M |
| InterestIncomeNonOperating | 16.97M | 21.41M | 19.56M | 609.00K |
| OperatingIncome | -187.83M | -182.18M | -282.49M | -144.25M |
| OperatingExpense | 202.24M | 190.97M | 284.70M | 247.39M |
| OtherOperatingExpenses | -5.68M | -5.60M | -5.29M | -6.08M |
| DepreciationAmortizationDepletionIncomeStatement | 1.91M | 2.11M | 2.05M | 1.18M |
| DepreciationAndAmortizationInIncomeStatement | 1.91M | 2.11M | 2.05M | 1.18M |
| DepreciationIncomeStatement | 1.91M | 2.11M | 2.05M | 1.18M |
| ResearchAndDevelopment | 140.67M | 143.78M | 214.86M | 197.59M |
| SellingGeneralAndAdministration | 65.34M | 50.68M | 73.08M | 54.70M |
| GeneralAndAdministrativeExpense | 65.34M | 50.68M | 73.08M | 54.70M |
| OtherGandA | 28.50M | 16.05M | 30.39M | 17.33M |
| RentAndLandingFees | 1.79M | 1.36M | 900.00K | 820.00K |
| SalariesAndWages | 35.04M | 33.27M | 41.78M | 36.54M |
| GrossProfit | 14.41M | 8.79M | 2.21M | 103.14M |
| CostOfRevenue | 1.69M | 18.33M | 13.63M | 3.34M |
| TotalRevenue | 16.10M | 27.12M | 15.84M | 106.48M |
| OperatingRevenue | 16.10M | 27.12M | 15.84M | 106.48M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 62.53M | 48.99M | 47.83M | 46.97M |
| ShareIssued | 62.53M | 48.99M | 47.83M | 46.97M |
| TotalDebt | 63.39M | 66.06M | 138.41M | 142.89M |
| TangibleBookValue | 100.76M | -100.21M | 120.81M | 391.65M |
| InvestedCapital | 248.60M | 44.57M | 309.42M | 578.80M |
| WorkingCapital | 593.07M | 350.24M | 578.18M | 400.86M |
| NetTangibleAssets | 100.76M | -100.21M | 120.81M | 391.65M |
| CapitalLeaseObligations | 13.69M | 14.74M | 36.66M | 40.10M |
| CommonStockEquity | 198.90M | -6.75M | 207.67M | 476.01M |
| TotalCapitalization | 248.60M | 44.57M | 309.42M | 578.80M |
| TotalEquityGrossMinorityInterest | 198.90M | -6.75M | 207.67M | 476.01M |
| StockholdersEquity | 198.90M | -6.75M | 207.67M | 476.01M |
| GainsLossesNotAffectingRetainedEarnings | -58.22M | -52.80M | -53.55M | -58.29M |
| OtherEquityAdjustments | -58.22M | -52.80M | -53.55M | -58.29M |
| RetainedEarnings | -1.33B | -1.13B | -890.41M | -581.93M |
| AdditionalPaidInCapital | 1.58B | 1.17B | 1.15B | 1.11B |
| CapitalStock | 3.69M | 2.94M | 2.88M | 2.84M |
| CommonStock | 3.69M | 2.94M | 2.88M | 2.84M |
| TotalLiabilitiesNetMinorityInterest | 626.01M | 563.29M | 624.02M | 228.96M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 563.09M | 523.24M | 550.34M | 153.04M |
| OtherNonCurrentLiabilities | 495.59M | 453.73M | 412.74M | 10.27M |
| NonCurrentDeferredLiabilities | 7.97M | 7.04M | 7.54M | 8.26M |
| NonCurrentDeferredTaxesLiabilities | 7.97M | 7.04M | 7.54M | 8.26M |
| LongTermDebtAndCapitalLeaseObligation | 59.53M | 62.46M | 130.06M | 134.51M |
| LongTermCapitalLeaseObligation | 9.83M | 11.14M | 28.32M | 31.72M |
| LongTermDebt | 49.70M | 51.32M | 101.75M | 102.79M |
| CurrentLiabilities | 62.92M | 40.05M | 73.67M | 75.92M |
| OtherCurrentLiabilities | 23.46M | 6.83M | 29.65M | 25.98M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 3.86M | 3.60M | 8.34M | 8.38M |
| CurrentCapitalLeaseObligation | 3.86M | 3.60M | 8.34M | 8.38M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.94M | 12.29M | 16.26M | 17.20M |
| PayablesAndAccruedExpenses | 25.66M | 17.34M | 19.42M | 24.35M |
| CurrentAccruedExpenses | 20.49M | 10.11M | 12.83M | 13.37M |
| Payables | 5.17M | 7.23M | 6.59M | 10.98M |
| AccountsPayable | 5.17M | 7.23M | 6.59M | 10.98M |
| TotalAssets | 824.91M | 556.54M | 831.69M | 704.96M |
| TotalNonCurrentAssets | 168.92M | 166.25M | 179.84M | 228.19M |
| OtherNonCurrentAssets | 5.56M | 1.40M | 3.18M | 6.06M |
| NonCurrentDeferredAssets | 8.65M | 9.86M | 12.28M | 14.53M |
| NonCurrentDeferredTaxesAssets | 8.65M | 9.86M | 12.28M | 14.53M |
| InvestmentsAndAdvances | 30.24M | 27.46M | 2.18M | 39.98M |
| OtherInvestments | 30.24M | 27.46M | 2.18M | |
| InvestmentinFinancialAssets | 0.00 | 39.98M | 0.00 | |
| HeldToMaturitySecurities | 0.00 | 39.98M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 98.14M | 93.46M | 86.86M | 84.36M |
| OtherIntangibleAssets | 72.79M | 71.04M | 60.48M | 58.78M |
| Goodwill | 25.36M | 22.41M | 26.38M | 25.58M |
| NetPPE | 26.32M | 34.07M | 75.34M | 83.26M |
| AccumulatedDepreciation | -43.74M | -31.66M | -55.67M | -44.13M |
| GrossPPE | 70.06M | 65.73M | 131.01M | 127.38M |
| Leases | 28.19M | 24.81M | 46.51M | 44.87M |
| ConstructionInProgress | 0.00 | 5.67M | 5.41M | 5.07M |
| OtherProperties | 37.52M | 37.01M | 72.45M | 72.12M |
| MachineryFurnitureEquipment | 4.36M | 3.91M | 6.38M | 4.99M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 655.99M | 390.29M | 651.85M | 476.77M |
| OtherCurrentAssets | 7.08M | 7.61M | 2.65M | 2.81M |
| PrepaidAssets | 20.51M | 9.28M | 15.09M | 11.82M |
| Inventory | 0.00 | 12.02M | 6.92M | 0.00 |
| FinishedGoods | 0.00 | 758.00K | 1.47M | 0.00 |
| WorkInProcess | 0.00 | 4.11M | 1.87M | 0.00 |
| RawMaterials | 0.00 | 7.16M | 3.58M | 0.00 |
| Receivables | 5.86M | 5.88M | 4.19M | 102.38M |
| AccountsReceivable | 5.86M | 5.88M | 4.19M | 102.38M |
| CashCashEquivalentsAndShortTermInvestments | 622.54M | 367.52M | 617.89M | 352.84M |
| OtherShortTermInvestments | 542.30M | 208.59M | 376.53M | 124.83M |
| CashAndCashEquivalents | 80.24M | 158.93M | 241.36M | 228.01M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -178.40M | -194.42M | -153.08M | -162.75M |
| RepaymentOfDebt | 0.00 | -53.05M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 64.07M | |
| IssuanceOfCapitalStock | 391.90M | 2.12M | 308.00K | 1.45M |
| CapitalExpenditure | -439.00K | -11.69M | -7.15M | -17.69M |
| InterestPaidSupplementalData | 25.07M | 20.57M | 16.88M | 9.25M |
| EndCashPosition | 81.80M | 160.33M | 244.54M | 231.17M |
| BeginningCashPosition | 160.33M | 244.54M | 231.17M | 559.35M |
| EffectOfExchangeRateChanges | 5.66M | -4.97M | 2.27M | -1.83M |
| ChangesInCash | -84.18M | -79.25M | 11.11M | -326.35M |
| FinancingCashFlow | 415.40M | -59.49M | 362.72M | 1.45M |
| CashFlowFromContinuingFinancingActivities | 415.40M | -59.49M | 362.72M | 1.45M |
| NetOtherFinancingCharges | -8.56M | 362.41M | -1.33M | |
| ProceedsFromStockOptionExercised | 23.50M | 0.00 | 0.00 | 2.80M |
| NetCommonStockIssuance | 391.90M | 2.12M | 308.00K | 1.45M |
| CommonStockIssuance | 391.90M | 2.12M | 308.00K | 1.45M |
| NetIssuancePaymentsOfDebt | 0.00 | -53.05M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | 0.00 | -53.05M | 0.00 | 0.00 |
| LongTermDebtPayments | 0.00 | -53.05M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 64.07M | |
| InvestingCashFlow | -321.62M | 162.97M | -205.69M | -182.73M |
| CashFlowFromContinuingInvestingActivities | -321.62M | 162.97M | -205.69M | -182.73M |
| NetInvestmentPurchaseAndSale | -321.18M | 174.66M | -198.53M | -163.15M |
| SaleOfInvestment | 337.19M | 534.50M | 167.91M | 0.00 |
| PurchaseOfInvestment | -658.38M | -359.84M | -366.44M | -163.15M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -1.90M | -49.95M |
| PurchaseOfBusiness | 0.00 | 0.00 | -1.90M | -49.95M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -439.00K | -11.69M | -7.15M | -17.69M |
| PurchaseOfPPE | -439.00K | -11.69M | -7.15M | -17.69M |
| OperatingCashFlow | -177.96M | -182.73M | -145.93M | -145.06M |
| CashFlowFromContinuingOperatingActivities | -177.96M | -182.73M | -145.93M | -145.06M |
| ChangeInWorkingCapital | -6.79M | -3.94M | 82.44M | -43.38M |
| ChangeInPayablesAndAccruedExpense | 1.81M | -4.12M | -9.50M | 12.62M |
| ChangeInAccruedExpense | 4.47M | -5.64M | -5.33M | 3.38M |
| ChangeInPayable | -2.67M | 1.52M | -4.17M | 9.24M |
| ChangeInAccountPayable | -2.67M | 1.52M | -4.17M | 9.24M |
| ChangeInInventory | 0.00 | 2.42M | -6.74M | -6.92M |
| ChangeInReceivables | -8.60M | -2.24M | 98.68M | -49.08M |
| ChangesInAccountReceivables | -8.60M | -2.24M | -1.32M | -4.08M |
| OtherNonCashItems | 39.66M | 18.93M | 44.32M | 5.92M |
| StockBasedCompensation | 17.68M | 22.26M | 35.09M | 34.20M |
| AmortizationOfSecurities | -10.46M | -10.90M | -10.92M | 0.00 |
| DeferredTax | 1.59M | 2.43M | 1.92M | -1.47M |
| DeferredIncomeTax | 1.59M | 2.43M | 1.92M | -1.47M |
| DepreciationAmortizationDepletion | 14.76M | 12.64M | 11.90M | 8.54M |
| DepreciationAndAmortization | 14.76M | 12.64M | 11.90M | 8.54M |
| Depreciation | 14.76M | 12.64M | 11.90M | 8.54M |
| OperatingGainsLosses | -35.42M | 15.41M | -2.21M | -22.08M |
| GainLossOnInvestmentSecurities | -12.40M | 6.84M | ||
| NetForeignCurrencyExchangeGainLoss | -23.02M | 15.41M | -2.21M | -22.08M |
| NetIncomeFromContinuingOperations | -198.97M | -239.56M | -308.48M | -126.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for QURE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|